Aquestive Therapeutics (AQST) News Today $3.10 +0.01 (+0.32%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in DecemberAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 10,480,000 shares, an increase of 8.6% from the December 15th total of 9,650,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is presently 6.8 days.January 19 at 9:13 AM | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus Target Price from AnalystsShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to tJanuary 18 at 1:28 AM | marketbeat.comPromising Pipeline and Solid Financials: Analyst’s Buy Rating on Aquestive TherapeuticsJanuary 15, 2025 | markets.businessinsider.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from AnalystsShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned a consensus rating of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issuedJanuary 15, 2025 | marketbeat.comAquestive Therapeutics: Promising Growth Trajectory with Strategic Initiatives and Strong Market PotentialJanuary 14, 2025 | markets.businessinsider.comAquestive Therapeutics provides business updateJanuary 13, 2025 | markets.businessinsider.comAquestive Therapeutics: Five Foci For 2025January 6, 2025 | seekingalpha.comState Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)State Street Corp boosted its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,496,739 shares of the company's stock after purchasing an additDecember 28, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial CorpStifel Financial Corp cut its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 75.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,944 shares of the company's stock after sellinDecember 28, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has earned a consensus rating of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy ratDecember 21, 2024 | marketbeat.comAquestive Therapeutics Gains Buy Rating Amid Orphan Drug Exclusivity and Promising Product PipelineDecember 20, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday.December 20, 2024 | marketbeat.comAquestive Therapeutics receives FDA ODE for Libervant Buccal FilmDecember 20, 2024 | markets.businessinsider.comAquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure TreatmentDecember 20, 2024 | finance.yahoo.comAquestive receives FDA Orphan Drug Exclusivity for LibervantDecember 20, 2024 | msn.comWellington Management Group LLP Acquires Shares of 185,191 Aquestive Therapeutics, Inc. (NASDAQ:AQST)Wellington Management Group LLP acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 185,191 shares of the companyDecember 20, 2024 | marketbeat.comCantor Fitzgerald Forecasts AQST FY2024 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Aquestive Therapeutics in a report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the compaDecember 19, 2024 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Stock, Insider Trading ActivityDecember 18, 2024 | benzinga.comCantor Fitzgerald Initiates Coverage of Aquestive Therapeutics (AQST) with Overweight RecommendationDecember 17, 2024 | msn.comAquestive Therapeutics initiated with an Overweight at Cantor FitzgeraldDecember 17, 2024 | markets.businessinsider.comDeveloper Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge UpsideDecember 17, 2024 | finance.yahoo.comAquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last yearDecember 17, 2024 | finance.yahoo.comCantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST)Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a report on Tuesday. They set an "overweight" rating and a $17.00 price objective on the stock.December 17, 2024 | marketbeat.comVerition Fund Management LLC Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Verition Fund Management LLC bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 199,729 shares of the companDecember 9, 2024 | marketbeat.comAquestive Therapeutics Says FDA Provides Positive Feedback On NDA Submission For AnaphylmDecember 3, 2024 | markets.businessinsider.comAquestive Therapeutics: Promising FDA Feedback and Solid Foundation Support Buy RatingDecember 3, 2024 | markets.businessinsider.comAquestive Therapeutics (AQST) Receives a Buy from Lake StreetDecember 3, 2024 | markets.businessinsider.comAquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual FilmDecember 2, 2024 | markets.businessinsider.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Down 6.0% in OctoberAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 10,140,000 shares, a decrease of 6.0% from the October 15th total of 10,790,000 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is presently 7.6 days.November 18, 2024 | marketbeat.comGSA Capital Partners LLP Has $683,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)GSA Capital Partners LLP lifted its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 525.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 137,151 shares of the company's stock after purchasing an additional 115,223 shares during theNovember 18, 2024 | marketbeat.comIs Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comChartwell Investment Partners LLC Acquires Shares of 107,550 Aquestive Therapeutics, Inc. (NASDAQ:AQST)Chartwell Investment Partners LLC bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 107,550 shares of thNovember 14, 2024 | marketbeat.comPositive Developments and Strategic Partnerships Justify Buy Rating for Aquestive TherapeuticsNovember 11, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for AQST EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Aquestive Therapeutics in a report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the comNovember 8, 2024 | marketbeat.comLeerink Partnrs Has Strong Estimate for AQST FY2024 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst R. Ruiz now anticipates thNovember 8, 2024 | marketbeat.comAquestive Therapeutics Announces Board and Committee ChangesNovember 7, 2024 | markets.businessinsider.comAquestive Therapeutics: Strong Buy Rating Driven by Robust Revenue Performance and Strategic Positioning in Allergy TreatmentNovember 7, 2024 | markets.businessinsider.comAquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 6, 2024 | finance.yahoo.comPromising Future and Strategic Advancements: Buy Recommendation for Aquestive TherapeuticsNovember 6, 2024 | markets.businessinsider.comLake Street Sticks to Their Buy Rating for Aquestive Therapeutics (AQST)November 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Strong Product Pipeline and Financial StabilityNovember 6, 2024 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...November 6, 2024 | finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday.November 6, 2024 | marketbeat.comAquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comAquestive: Rare Opportunity With Dual Platform StrategyNovember 5, 2024 | seekingalpha.comAquestive Therapeutics (NASDAQ:AQST) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPSAquestive Therapeutics (NASDAQ:AQST - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analysts' expectations of $12.69 million. During the same quarter in the prior year, the company earned ($0.03) EPS.November 5, 2024 | marketbeat.comAquestive Therapeutics Optimistic Financial and Strategic OutlookNovember 5, 2024 | markets.businessinsider.comAquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 4, 2024 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To ExpectNovember 4, 2024 | finance.yahoo.comAquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 4, 2024 | globenewswire.com Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Media Mentions By Week AQST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.780.44▲Average Medical News Sentiment AQST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼63▲AQST Articles Average Week Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNDX News COLL News ALVR News SYRE News ELVN News GYRE News ADPT News NTLA News ZYME News RCKT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQST Stock Alerts